Neuro-Oncology News

September is Childhood Cancer Awareness Month, a campaign to spotlight the types of cancer that largely affect children, draw attention to survivorship issues, and raise funds for research and family support.

Patients with cancer did not have significant reductions in treatment costs or health care use when treated by physicians at accountable care organizations compared to those treated by non-ACOs, according to a study of Medicare claims published in Journal of Clinical Oncology.

A Harvard Medical School project will mine multiple data sources to try to determine why some patients are more likely to have exceptional responses to cancer treatments.

Only 40% of survivors of pediatric central nervous system tumors achieved complete independence, according to results from a single institution cohort study.

The use of biosimilar biologics filgrastim-sndz and tbo-filgrastim increased substantially among Medicare beneficiaries between 2014 and 2016, according to a research letter published in JAMA.

In August, the FDA issued several approvals and review designations across the field of oncology. HemOnc Today has compiled a list of the past month’s approvals, updates and submissions.

The FDA granted the PapGene liquid biopsy test breakthrough device designation for the detection of cancer among people aged older than 65 years, according to the manufacturer.

Adolescents with cancer treated at pediatric institutions had greater health care use and higher costs than those treated at adult institutions, according to a Canadian population cohort study.

Sixty-five percent of adult survivors of childhood cancer experienced financial hardships related to their earlier diagnosis, according to findings from a cross-sectional study.

Children aged younger than 18 years who underwent CT scans may be at increased risk for developing brain tumors from the high-dose radiation exposure, according to results of a retrospective cohort study.